Engagement of renin-angiotensin system in prostate cancer

Current Cancer Drug Targets

Volumn 11, Issue 4, 2011, Pages 442-450

  Uemura, H ^a   Hoshino, K ^a   Kubota, Y ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II; Angiotensin II receptor blocker; Castration resistant prostate cancer; Local RAS; Prostate cancer; Renin angiotensin system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BLOOD PRESSURE REGULATION; CARCINOGENESIS; CHEMOPROPHYLAXIS; ELECTROLYTE BALANCE; FLUID BALANCE; HUMAN; HYPERTENSION; NONHUMAN; PREVALENCE; PROSTATE CANCER; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM;

EID: 79955572398     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800911795538101     Document Type: Review

References (94)

1. Heffelfinger, S. C. The renin angiotensin system in the regulation of angiogenesis. Curr. Pharm. Des. 2007, 13, 1215-1229.
2. Lever, A. F.; Hole, D. J.; Gillis, C. R.; McCallum, I. R.; McInnes, G. T.; MacKinnon, P. L.; Meredith, P. A.; Murray, L. S.; Reid, J. L.; Robertson, J. W. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998, 352, 179-184.
3. Ronquist, G.; Rodriguez, L. A.; Ruigomez, A.; Johansson, S.; Wallander, M. A.; Frithz, G.; Svardsudd, K. Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate 2004, 58, 50-56.
4. Kambayashi, Y.; Bardhan, S.; Takahashi, K.; Tsuzuki, S.; Inui, H.; Hamakubo, T.; Inagami, T. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J. Biol. Chem. 1993, 268, 24543-24546.
5. Mukoyama, M.; Nakajima, M.; Horiuchi, M.; Sasamura, H.; Pratt, R. E.; Dzau, V. J. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J. Biol. Chem. 1993, 268, 24539-24542.
6. Fabiani, M. E.; Johnston, C. I. Spectrum of use for the angiotensinreceptor blocking drugs. Curr. Hypertens. Rep. 1999, 1, 394-401.
7. 2 receptors. Kidney Int. Suppl. 1998, 67, S95-99.
8. Dzau, V. J. Cell biology and genetics of angiotensin in cardiovascular disease. J. Hypertens. Suppl. 1994, 12, S3-10.
9. Huckle, W. R.; Earp, H. S. Regulation of cell proliferation and growth by angiotensin II. Prog. Growth Factor Res. 1994, 5, 177-194.
10. Rosendorff, C. The renin-angiotensin system and vascular hypertrophy. J. Am. Coll. Cardiol. 1996, 28, 803-812.
11. Engeli, S.; Negrel, R.; Sharma, A. M. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000, 35, 1270-1277.
12. Davisson, R. L. Physiological genomic analysis of the brain reninangiotensin system. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 285, R498-511.
13. Mulrow, P. J. The intrarenal renin-angiotensin system. Curr. Opin. Nephrol. Hypertens. 1993, 2, 41-44.
14. Chappell, M. C.; Diz, D. I.; Gallagher, P. E. The renin-angiotensin system and the exocrine pancreas. JOP 2001, 2, 33-39.
15. Speth, R. C.; Daubert, D. L.; Grove, K. L. Angiotensin II: a reproductive hormone too? Regul. Pept. 1999, 79, 25-40.
16. Uemura, H.; Hasumi, H.; Ishiguro, H.; Teranishi, J.; Miyoshi, Y.; Kubota, Y. Renin-angiotensin system is an important factor in hormone refractory prostate cancer. Prostate 2006, 66, 822-830.
17. Nielsen, A. H.; Schauser, K. H.; Poulsen, K. Current topic: the uteroplacental renin-angiotensin system. Placenta 2000, 21, 468-477.
18. Klickstein, L. B.; Kaempfer, C. E.; Wintroub, B. U. The granulocyte-angiotensin system. Angiotensin I-converting activity of cathepsin G. J. Biol. Chem. 1982, 257, 15042-15046.
19. Schiller, P. W.; Demassieux, S.; Boucher, R. Substrate specificity of tonin from rat submaxillary gland. Circ. Res. 1976, 39, 629-632.
20. Baltatu, O.; Nishimura, H.; Hoffmann, S.; Stoltenburg, G.; Haulica, I. D.; Lippoldt, A.; Ganten, D.; Urata, H. High levels of human chymase expression in the pineal and pituitary glands. Brain Res. 1997, 752, 269-278.
21. Tahmasebi, M.; Puddefoot, J. R.; Inwang, E. R.; Goode, A. W.; Carpenter, R.; Vinson, G. P. Transcription of the prorenin gene in normal and diseased breast. Eur. J. Cancer 1998, 34, 1777-1782.
22. 1 angiotensin II receptor subtype in the human larynx and squamous laryngeal carcinoma. Cancer Lett. 1996, 110, 19-27.
23. Fujimoto, Y.; Sasaki, T.; Tsuchida, A.; Chayama, K. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett. 2001, 495, 197-200.
24. 1 receptor involving protein kinase C-and mitogen-activated protein kinase-dependent signaling pathway. J. Clin. Endocrinol. Metab. 2003, 88, 3973-3982.
25. Uemura, H.; Ishiguro, H.; Nakaigawa, N.; Nagashima, Y.; Miyoshi, Y.; Fujinami, K.; Sakaguchi, A.; Kubota Y. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol. Cancer Ther. 2003, 2, 1139-1147.
26. O'Mahony, O. A.; Barker, S.; Puddefoot, J. R.; Vinson, G. P. Synthesis and secretion of angiotensin II by the prostate gland in vitro. Endocrinology 2005, 146, 392-398.
27. Dinh, D. T.; Frauman, A. G.; Somers, G. R.; Ohishi, M.; Zhou, J.; Casley, D. J.; Johnston, C. I.; Fabiani, M. E. Evidence for activation of the renin-angiotensin system in the human prostate: increased angiotensin II and reduced AT(1) receptor expression in benign prostatic hyperplasia. J. Pathol. 2002, 196, 213-219.
28. Lin, J.; Freeman, M. R. Transactivation of ErbB1 and ErbB2 receptors by angiotensin II in normal human prostate stromal cells. Prostate 2003, 54, 1-7.
29. Chow, L.; Rezmann, L.; Imamura, K.; Wang, L.; Catt, K.; Tikellis, C.; Louis, W. J.; Frauman, A. G.; Louis, S. N. Functional angiotensin II type 2 receptors inhibit growth factor signaling in LNCaP and PC3 prostate cancer cell lines. Prostate 2008, 68, 651-660.
30. Saridogan, E.; Djahanbakhch, O.; Puddefoot, J. R.; Demetroulis, C.; Collingwood, K.; Mehta, J. G.; Vinson, G. P. Angiotensin II receptors and angiotensin II stimulation of ciliary activity in human fallopian tube. J. Clin. Endocrinol. Metab. 1996, 81, 2719-2725.
31. Mahmood, T.; Djahanbakhch, O.; Burleigh, D. E.; Puddefoot, J. R.; O'Mahony, O. A.; Vinson, G. P. Effect of angiotensin II on ion transport across human Fallopian tube epithelial cells in vitro. Reproduction 2002, 124, 573-579.
32. Kosaka, T.; Miyajima, A.; Shirotake, S.; Kikuchi, E.; Hasegawa, M.; Mikami, S.; Oya, M. Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormonerefractory prostate cancer. Prostate 2010, 70, 162-169.
33. Asakura, M.; Kitakaze, M.; Takashima, S.; Liao, Y.; Ishikura, F.; Yoshinaka, T.; Ohmoto, H.; Node, K.; Yoshino, K.; Ishiguro, H.; Asanuma, H.; Sanada, S.; Matsumura, Y.; Takeda, H.; Beppu, S.; Tada, M.; Hori, M.; Higashiyama, S. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat. Med. 2002, 8, 35-40.
34. Deshayes, F.; Nahmias, C. Angiotensin receptors: a new role in cancer? Trends Endocrinol. Metab. 2005, 16, 293-299.
35. Tsuzuki, S.; Ichiki, T.; Nakakubo, H.; Kitami, Y.; Guo, D. F.; Shirai, H.; Inagami, T. Molecular cloning and expression of the gene encoding human angiotensin II type 2 receptor. Biochem. Biophys. Res. Commun. 1994, 200, 1449-1454.
36. 2-receptors depend on down-regulation of SM-20. Lab. Invest. 2002, 82, 1305-1317.
37. Dinh, D. T.; Frauman, A. G.; Sourial, M.; Casley, D. J.; Johnston, C. I.; Fabiani, M. E. Identification, distribution, and expression of angiotensin II receptors in the normal human prostate and benign prostatic hyperplasia. Endocrinology 2001, 142, 1349-1356.
38. Wennemuth, G.; Aumuller, G. Angiotensin II-mediated calcium signals and mitogenesis in human prostate stromal cell line hPCPs. Br. J. Pharmacol. 2005, 144, 3-10.
39. 2 receptor: new insights into an old system. Regul. Pept. 2001, 99, 175-182.
40. Nio, Y.; Matsubara, H.; Murasawa, S.; Kanasaki, M.; Inada, M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J. Clin. Invest. 1995, 95, 46-54.
41. Yang, Z.; Bove, C. M.; French, B. A.; Epstein, F. H.; Berr, S. S.; DiMaria, J. M.; Gibson, J. J.; Carey, R. M.; Kramer, C. M. Angiotensin II type 2 receptor overexpression preserves left ventricular function after myocardial infarction. Circulation 2002, 106, 106-111.
42. 2 receptor-interacting protein, ATIP. J. Biol. Chem. 2004, 279, 28989-28997.
43. Bedecs, K.; Elbaz, N.; Sutren, M.; Masson, M.; Susini, C.; Strosberg, A. D.; Nahmias, C. Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase. Biochem. J. 1997, 325, 449-454.
44. 2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol. Cell. Endocrinol. 1996, 122, 59-67.
45. 1 receptor: gain-of-function study using gene transfer. Proc. Natl. Acad. Sci. USA 1995, 92, 10663-10667.
46. Albiston, A. L.; McDowall, S. G.; Matsacos, D.; Sim, P.; Clune, E.; Mustafa, T.; Lee, J.; Mendelsohn, F. A.; Simpson, R. J.; Connolly, L. M.; Chai, S. Y. Evidence that the angiotensin IV (AT(4) receptor is the enzyme insulin-regulated aminopeptidase. J. Biol. Chem. 2001, 276, 48623-48626.
47. Chai, S. Y.; Fernando, R.; Peck, G.; Ye, S. Y.; Mendelsohn, F. A.; Jenkins, T. A.; Albiston, A. L. The angiotensin IV/AT4 receptor. Cell. Mol. Life Sci. 2004, 61, 2728-2737.
48. Wright, J. W.; Harding, J. W. Important role for angiotensin III and IV in the brain renin-angiotensin system. Brain Res. Brain Res. Rev. 1997, 25, 96-124.
49. Dinh, D. T.; Frauman, A. G.; Casley, D. J.; Johnston, C. I.; Fabiani, M. E. Angiotensin AT(4) receptors in the normal human prostate and benign prostatic hyperplasia. Mol. Cell. Endocrinol. 2001, 184, 187-192.
50. Kenny, A. J.; O'Hare, M. J.; Gusterson, B. A. Cell-surface peptidases as modulators of growth and differentiation. Lancet 1989, 2, 785-787.
51. King, K. A.; Hua, J.; Torday, J. S.; Drazen, J. M.; Graham, S. A.; Shipp, M. A.; Sunday, M. E. CD10/neutral endopeptidase 24.11 regulates fetal lung growth and maturation in utero by potentiating endogenous bombesin-like peptides. J. Clin. Invest. 1993, 91, 1969-1973.
52. Shipp, M. A.; Tarr, G. E.; Chen, C. Y.; Switzer, S. N.; Hersh, L. B.; Stein, H.; Sunday, M. E.; Reinherz, E. L. CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc. Natl. Acad. Sci. USA 1991, 88, 10662-10666.
53. Teranishi, J.; Ishiguro, H.; Hoshino, K.; Noguchi, K.; Kubota, Y.; Uemura, H. Evaluation of role of angiotensin III and aminopeptidases in prostate cancer cells. Prostate 2008, 68, 1666-1673.
54. Quaroni, A.; Nichols, B. L.; Quaroni, E.; Hurst, K.; Herrera, L.; Weiser, M. M.; Hamilton, S. R. Expression and different polarity of aminopeptidase N in normal human colonic mucosa and colonic tumors. Int. J. Cancer 1992, 51, 404-411.
55. Dixon, J.; Kaklamanis, L.; Turley, H.; Hickson, I. D.; Leek, R. D.; Harris, A. L.; Gatter, K. C. Expression of aminopeptidase-n (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin. J. Clin. Pathol. 1994, 47, 43-47.
56. Bogenrieder, T.; Finstad, C. L.; Freeman, R. H.; Papandreou, C. N.; Scher, H. I.; Albino, A. P.; Reuter, V. E.; Nanus, D. M. Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue. Prostate 1997, 33, 225-232.
57. Ishii, K.; Usui, S.; Yamamoto, H.; Sugimura, Y.; Tatematsu, M.; Hirano, K. Decreases of metallothionein and aminopeptidase N in renal cancer tissues. J. Biochem. 2001, 129, 253-258.
58. Varona, A.; Blanco, L.; Lopez, J. I.; Gil, J.; Agirregoitia, E.; Irazusta, J.; Larrinaga, G. Altered levels of acid, basic, and neutral peptidase activity and expression in human clear cell renal cell carcinoma. Am. J. Physiol. Renal Physiol. 2007, 292, F780-788.
59. Menrad, A.; Speicher, D.; Wacker, J.; Herlyn, M. Biochemical and functional characterization of aminopeptidase N expressed by human melanoma cells. Cancer Res. 1993, 53, 1450-1455.
60. Saiki, I.; Fujii, H.; Yoneda, J.; Abe, F.; Nakajima, M.; Tsuruo, T.; Azuma, I. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int. J. Cancer 1993, 54, 137-143.
61. Yigit, B.; Bozkurt, N.; Narter, F.; Yilmaz, H.; Yucebas, E.; Isbir, T. Effects of ACE I/D polymorphism on prostate cancer risk, tumor grade and metastatis. Anticancer Res. 2007, 27, 933-936.
62. Sierra Diaz, E.; Sanchez Corona, J.; Rosales Gomez, R. C.; Gutierrez Rubio, S. A.; Vazquez Camacho, J. G.; Solano Moreno, H.; Moran Moguel, M. C. Angiotensin-converting enzyme insertion/deletion and angiotensin type 1 receptor A1166C polymorphisms as genetic risk factors in benign prostatic hyperplasia and prostate cancer. J. Renin Angiotensin Aldosterone Syst. 2009, 10, 241-246.
63. van der Knaap, R.; Siemes, C.; Coebergh, J. W.; van Duijn, C. M.; Hofman, A.; Stricker, B. H. Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study. Cancer 2008, 112, 748-757.
64. Ronquist, G.; Frithz, G.; Wang, Y. H.; Lindeborg, T. Captopril may reduce biochemical (prostate-specific antigen) failure following radical prostatectomy for clinically localized prostate cancer. Scand. J. Urol. Nephrol. 2009, 43, 32-36.
65. Small, W. Jr.; Molteni, A.; Kim, Y. T.; Taylor, J. M.; Chen, Z.; Ward, W. F. Captopril modulates hormone receptor concentration and inhibits proliferation of human mammary ductal carcinoma cells in culture. Breast Cancer Res. Treat. 1997, 44, 217-224.
66. Yoshiji, H.; Kuriyama, S.; Kawata, M.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Nakatani, T.; Tsujinoue, H.; Fukui, H. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin. Cancer Res. 2001, 7, 1073-1078.
67. Chen, L.; Re, R. N.; Prakash, O.; Mondal, D. Angiotensinconverting enzyme inhibition reduces neuroblastoma cell growth rate. Proc. Soc. Exp. Biol. Med. 1991, 196, 280-283.
68. Reddy, M. K.; Baskaran, K.; Molteni, A. Inhibitors of angiotensinconverting enzyme modulate mitosis and gene expression in pancreatic cancer cells. Proc. Soc. Exp. Biol. Med. 1995, 210, 221-226.
69. Hii, S. I.; Nicol, D. L.; Gotley, D. C.; Thompson, L. C.; Green, M. K.; Jonsson, J. R. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br. J. Cancer 1998, 77, 880-883.
70. Volpert, O.V.; Ward, W. F.; Lingen, M. W.; Chesler, L.; Solt, D. B.; Johnson, M. D.; Molteni, A.; Polverini, P. J.; Bouck, N. P. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J. Clin. Invest. 1996, 98, 671-679.
71. Uemura, H.; Hasumi, H.; Kawahara, T.; Sugiura, S.; Miyoshi, Y.; Nakaigawa, N.; Teranishi, J.; Noguchi, K.; Ishiguro, H.; Kubota, Y. Pilot study of angiotensin II receptor blocker in advanced hormonerefractory prostate cancer. Int. J. Clin. Oncol. 2005, 10, 405-410.
72. Arafat, H. A.; Gong, Q.; Chipitsyna, G.; Rizvi, A.; Saa, C. T.; Yeo, C. J. Antihypertensives as novel antineoplastics: angiotensin-Iconverting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J. Am. Coll. Surg. 2007, 204, 996-1005; discussion 1005-1006.
73. Egami, K.; Murohara, T.; Shimada, T.; Sasaki, K.; Shintani, S.; Sugaya, T.; Ishii, M.; Akagi, T.; Ikeda, H.; Matsuishi, T.; Imaizumi, T. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J. Clin. Invest. 2003, 112, 67-75.
74. Schupp, N.; Schmid, U.; Rutkowski, P.; Lakner, U.; Kanase, N.; Heidland, A.; Stopper, H. Angiotensin II-induced genomic damage in renal cells can be prevented by angiotensin II type 1 receptor blockage or radical scavenging. Am. J. Physiol. Renal Physiol. 2007, 292, F1427-1434.
75. Suganuma, T.; Ino, K.; Shibata, K.; Kajiyama, H.; Nagasaka, T.; Mizutani, S.; Kikkawa, F. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin. Cancer Res. 2005, 11, 2686-2694.
76. Yamagishi, T.; Uemura, H.; Nakaigawa, N.; Noguchi, K.; Kubota, Y. Angiotensin II blocker decreases serum prostate specific antigen in hormone refractory prostate cancer. J. Urol. 2005, 173, 441.
77. 1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma. Br. J. Cancer 2001, 85, 1396-1399.
78. 2 receptor blockade on the pathogenesis of renal fibrosis. Am. J. Physiol. 1999, 276, F39-45.
79. Li, H.; Qi, Y.; Li, C.; Braseth, L. N.; Gao, Y.; Shabashvili, A. E.; Katovich, M. J.; Sumners, C. Angiotensin type 2 receptor-mediated apoptosis of human prostate cancer cells. Mol. Cancer Ther. 2009, 8, 3255-3265.
80. Benson, S. C.; Pershadsingh, H. A.; Ho, C. I.; Chittiboyina, A.; Desai, P.; Pravenec, M.; Qi, N.; Wang, J.; Avery, M. A.; Kurtz, T. W. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004, 43, 993-1002.
81. Ishiguro, H.; Ishiguro, Y.; Kubota, Y.; Uemura, H. Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action. Prostate 2007, 67, 924-932.
82. Segawa, Y.; Yoshimura, R.; Hase, T.; Nakatani, T.; Wada, S.; Kawahito, Y.; Kishimoto, T.; Sano, H. Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate 2002, 51, 108-116.
83. Djakiew, D. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 2000, 42, 150-160.
84. Suzuki, Y.; Ruiz-Ortega, M.; Lorenzo, O.; Ruperez, M.; Esteban, V.; Egido, J. Inflammation and angiotensin II. Int. J. Biochem. Cell Biol. 2003, 35, 881-900.
85. Uemura, H.; Ishiguro, H.; Nagashima, Y.; Sasaki, T.; Nakaigawa, N.; Hasumi, H.; Kato, S.; Kubota, Y. Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells. Mol. Cancer Ther. 2005, 4, 1699-1709.
86. Scher, H. I.; Sarkis, A.; Reuter, V.; Cohen, D.; Netto, G.; Petrylak, D.; Lianes, P.; Fuks, Z.; Mendelsohn, J.; Cordon-Cardo, C. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin. Cancer Res. 1995, 1, 545-550.
87. Bok, R. A.; Halabi, S.; Fei, D. T.; Rodriquez, C. R.; Hayes, D. F.; Vogelzang, N. J.; Kantoff, P.; Shuman, M. A.; Small, E. J. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res. 2001, 61, 2533-2536.
88. Drachenberg, D. E.; Elgamal, A. A.; Rowbotham, R.; Peterson, M.; Murphy, G. P. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999, 41, 127-133.
89. Small, E. J.; Reese, D. M.; Um, B.; Whisenant, S.; Dixon, S. C.; Figg, W. D. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. 1999, 5, 1738-1744.
90. Lee, S. O.; Lou, W.; Johnson, C. S.; Trump, D. L.; Gao, A. C. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. Prostate 2004, 60, 178-186.
91. Voronov, E.; Shouval, D. S.; Krelin, Y.; Cagnano, E.; Benharroch, D.; Iwakura, Y.; Dinarello, C. A.; Apte, R. N. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl. Acad. Sci. USA 2003, 100, 2645-2650.
92. Lee, L. F.; Louie, M. C.; Desai, S. J.; Yang, J.; Chen, H. W.; Evans, C. P.; Kung, H. J. Interleukin-8 confers androgenindependent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene 2004, 23, 2197-2205.
93. Uemura, H.; Ishiguro, H.; Kubota, Y. Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment. Int. J. Urol. 2008, 15, 19-26.
94. Ohta, M.; Kitadai, Y.; Tanaka, S.; Yoshihara, M.; Yasui, W.; Mukaida, N.; Haruma, K.; Chayama, K. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas. Int. J. Oncol. 2003, 22, 773-778.